Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer

Treatment Patterns and Clinical Outcomes Among Metastatic Non–Small-Cell Lung Cancer Patients Treated in the Community Practice Setting

(2018) Eric Nadler et al.   Clinical Lung Cancer

Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non–Small Cell Lung Cancer in the Community Oncology Setting

(2018) Carolyn J. Presley et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Broad-Based Molecular Testing for Lung Cancer

(2018) Paul A. Bunn et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Personalized, molecularly matched combination therapies for treatment-na.

(2017) Jason K. Sicklick et al.   JOURNAL OF CLINICAL ONCOLOGY

Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer

(2017) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs

(2017) Derrick S. Haslem et al.   Journal of Oncology Practice

Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study

(2016) Jennifer J. Wheler et al.   CANCER RESEARCH

Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing

(2016) A. B. Schrock et al.   CLINICAL CANCER RESEARCH

The cost of molecular-guided therapy in oncology: a prospective cost study alongside the MOSCATO trial

(2016) Arnaud Pagès et al.   GENETICS IN MEDICINE

Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

(2016) Scott Gettinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Genomic Sequencing Procedure Microcosting Analysis and Health Economic Cost-Impact Analysis

(2016) Linda M. Sabatini et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

(2016) Fabrice Barlesi et al.   LANCET

Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience

(2016) M. Schwaederle et al.   MOLECULAR CANCER THERAPEUTICS

Clinical Implications of Genomic Discoveries in Lung Cancer

(2016) Charles Swanton et al.   NEW ENGLAND JOURNAL OF MEDICINE

Value-Based Care in Lung Cancer

(2016) K. D. Eaton et al.   ONCOLOGIST

Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials

(2016) James H. Suh et al.   ONCOLOGIST

Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK -Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization

(2016) Siraj M. Ali et al.   ONCOLOGIST

Real-World Patterns of EGFR Testing and Treatment with Erlotinib for Non-Small Cell Lung Cancer in the United States

(2016) Lindsey Enewold et al.   PLoS One

The next steps in next-gen sequencing of cancer genomes

(2015) D. Neil Hayes et al.   JOURNAL OF CLINICAL INVESTIGATION

Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine

(2015) Amanda J. Redig et al.   JOURNAL OF CLINICAL ONCOLOGY

Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non–small-cell Lung Cancer

(2015) Sarayut L Geater et al.   Journal of Thoracic Oncology

On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients

(2015) M. Schwaederle et al.   MOLECULAR CANCER THERAPEUTICS

NCI-MATCH trial pushes cancer umbrella trial paradigm

(2015) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

(2015) David M. Hyman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations

(2015) B. P. Levy et al.   ONCOLOGIST

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Clinical next-generation sequencing in patients with non-small cell lung cancer

(2014) Ian S. Hagemann et al.   CANCER

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

(2014) Mark G. Kris et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced Non–Small-Cell Lung Cancer

(2014) Fiona Blackhall et al.   Journal of Thoracic Oncology

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

(2014) Benjamin J. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

(2014) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing Panel

(2014) D. B. Johnson et al.   ONCOLOGIST

A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC)

(2014) Ansgar Lange et al.   BMC Pulmonary Medicine

The Impact of Genomic Changes on Treatment of Lung Cancer

(2013) Stephanie Cardarella et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)

(2013) G. Chen et al.   ANNALS OF ONCOLOGY

New Targetable Oncogenes in Non–Small-Cell Lung Cancer

(2013) Geoffrey R. Oxnard et al.   JOURNAL OF CLINICAL ONCOLOGY

Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma WithEGFRMutations

(2013) James Chih-Hsin Yang et al.   JOURNAL OF CLINICAL ONCOLOGY

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions

(2013) J. F. Gainor et al.   ONCOLOGIST

Mammography Screening: A New Estimate of Number Needed to Screen to Prevent One Breast Cancer Death

(2012) R. Edward Hendrick et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Genetic Changes in Squamous Cell Lung Cancer: A Review

(2012) Rebecca S. Heist et al.   Journal of Thoracic Oncology

Cost Effectiveness of Personalized Therapy for First-Line Treatment of Stage IV and Recurrent Incurable Adenocarcinoma of the Lung

(2012) Elizabeth A. Handorf et al.   Journal of Oncology Practice

Sex-Specific Prevalence of Adenomas, Advanced Adenomas, and Colorectal Cancer in Individuals Undergoing Screening Colonoscopy

(2011) Monika Ferlitsch et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Projections of the Cost of Cancer Care in the United States: 2010-2020

(2011) A. B. Mariotto et al.   JNCI-Journal of the National Cancer Institute

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

(2008) Giorgio Vittorio Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY